Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	345
Overall Study	STARTED	Placebo Q2W	172
Overall Study	Treated (Safety Population)	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	344
Overall Study	Treated (Safety Population)	Placebo Q2W	170
Overall Study	ITT Population	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	336
Overall Study	ITT Population	Placebo Q2W	167
Overall Study	mITT Population	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	333
Overall Study	mITT Population	Placebo Q2W	164
Overall Study	T1DM Participants	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	51
Overall Study	T1DM Participants	Placebo Q2W	25
Overall Study	T2DM Participants	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	294
Overall Study	T2DM Participants	Placebo Q2W	147
Overall Study	COMPLETED	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	312
Overall Study	COMPLETED	Placebo Q2W	157
Overall Study	NOT COMPLETED	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	33
Overall Study	NOT COMPLETED	Placebo Q2W	15

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02585778/flow